Clinical and Experimental Otorhinolaryngology Vol. 16, No. 2: 148-158, May 2023

Original Article



https://doi.org/10.21053/ceo.2022.01718 pISSN 1976-8710 eISSN 2005-0720

Efficacy of Steroid-Impregnated Spacers After Endoscopic Sinus Surgery in Chronic Rhinosinusitis: A Systematic Review and Meta-Analysis

Se Hwan Hwang¹ . Sung Won Kim² . Mohammed Abdullah Basurrah³ . Do Hyun Kim²

¹Department of Otolaryngology-Head and Neck Surgery, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea ²Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea ³Department of Surgery, College of Medicine, Taif University, Taif, Saudi Arabia

- **Objectives.** The aim of this study was to compare the effect of steroid-impregnated spacers to that of conventional management after endoscopic sinus surgery (ESS) in patients with chronic rhinosinusitis (CRS).
- **Methods.** Six databases were searched from inception until November 2022. Sixteen studies were found that compared the improvement of chronic sinusitis-related symptoms and postoperative outcomes between a steroid-impregnated spacer group and a control group (non-steroid-impregnated spacers). The Cochrane risk of bias tool (for randomized controlled studies) and the Newcastle-Ottawa Scale (for non-randomized controlled studies) were used to assess the quality of the works included.
- **Results.** Regarding the endoscopic findings, the degree of mucosal edema, ethmoid inflammation, crust formation at 2–3 months postoperatively, nasal discharge, polyposis, and scarring/synechia were significantly lower in the steroid-impregnated spacer group. The steroid-impregnated spacer group also showed significantly lower Lund–Kennedy scores and perioperative sinus endoscopy scores than the control group at 2–3 weeks postoperatively. Furthermore, the steroid-impregnated spacer group had lower rates of adhesions, middle turbinate lateralization, polypoid changes, the need for oral steroid use, the need for postoperative therapeutic interventions, and lysis of adhesions than controls. However, no significant between-group differences were found in short-term (2–3 weeks postoperatively) endoscopic findings regarding nasal discharge, postoperative crusting, polyposis, or scarring/synechia.
- **Conclusion.** Steroid-impregnated nasal packing reduced the rates of postoperative intervention and recurrent polyposis and inflammation in CRS patients undergoing ESS.

Keywords. Sinusitis; Operative Surgical Procedures; Nose; Steroids; Stents

INTRODUCTION

Revised January 19, 2023
Accepted February 15, 2023
Corresponding author: Do Hyun Kim
Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea
Tel: +82-2-2258-6112, Fax: +82-2-535-1354
Email: dohyuni9292@naver.com

• Received December 7, 2022

Chronic rhinosinusitis (CRS) is characterized by persistent inflammation of the sinus mucosa, which results in nasal congestion, postnasal drip, facial pressure, and decreased olfactory function [1,2]. Furthermore, it leads to chronic pain, depression, and social dysfunction, which impair quality of life [3]. Due to the high prevalence of CRS, the number of CRS cases that are intractable to medical treatment is also increasing. Accordingly, endoscopic sinus surgery (ESS) is becoming increasingly impor-

Copyright © 2023 by Korean Society of Otorhinolaryngology-Head and Neck Surgery.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

tant [4]. Although ESS is effective in resolving persistent CRS, local sinus inflammation may sometimes persist even after surgery, and surgical site adhesions and strictures may occur during the recovery process of the surgical site. This can slow recovery, potentially leading to the need for revision surgery [5,6]. To overcome this problem, steroid-impregnated spacers have been devised as a way to reduce local inflammation around the surgical area and prevent stenosis during postoperative recovery [7-23]. In this study, we reviewed the steroid-impregnated spacers reported to date and evaluated their effects on treatment outcomes using validated scales. Additionally, the rates of postoperative adverse outcomes such as adhesions, middle turbinate lateralization, the need for postoperative therapeutic interventions, scarring/synechia, and lysis of adhesions were compared with the control group. The goal of this meta-analysis of the literature on steroid-impregnated spacers was to comprehensively assess the efficacy of steroid-impregnated spacers for improving outcomes following ESS surgery. In addition, a subgroup analysis was performed to compare the effects of absorbable nasal dressing and drug-eluting sinus stents.

MATERIALS AND METHODS

Population, Intervention, Comparison, Outcomes and Study and selection criteria

The Population, Intervention, Comparison, Outcomes and Study (PICOS) of the study were as follows: (1) population: CRS patients who underwent functional ESS (primary or revision procedure); (2) intervention: steroid-impregnated packing, spacer, and stent; (3) comparison: packing, spacer, and stent without steroids; (4) outcomes: treatment and postoperative adverse outcomes; and (5) study design: no restrictions. Review articles, case reports, and studies with missing diagnostic data were excluded. Our institution does not require institutional review board approval for a systematic review and meta-analysis based exclusively on the published literature.

H I G H L I G H T S

- Steroid-impregnated spacers can effectively deliver a corticosteroid to the target site.
- Steroid-impregnated spacers improve the surgical outcomes of endoscopic sinus surgery patients, such as the degree of mucosal edema, ethmoid inflammation, crust formation, nasal discharge, polypoid changes, polyposis, Lund-Kennedy score, and the need for oral steroid usage.
- Steroid-impregnated spacers reduce postoperative adhesions, middle turbinate lateralization, scarring/synechia, and the need for postoperative therapeutic interventions.

Search strategy

The following databases were searched from inception to November 2022: PubMed, Scopus, Embase, the Web of Science, Google Scholar, and the Cochrane database. Search terms and queries are listed in Supplementary Table 1. Two independent researchers (DHK and MAB) reviewed and screened the titles and abstracts of all potentially eligible studies and excluded those un related to our topic. If the abstract alone was not sufficient for determining whether a study was suitable for inclusion, the full text was checked. If the opinions of the two researchers differed, study eligibility was decided via discussion with a third reviewer (SWK). A flowchart of the study selection process is presented in Fig. 1. The study protocol is registered on Open Science Framework (https://osf.io/fhc42/).

Data extraction and risk of bias assessment

We extracted the following data from eligible studies: the number of patients, scale used for assessing endoscopic findings, incidence of postoperative adverse events (adhesions, middle turbinate lateralization, polypoid change, and the need for postoperative therapeutic intervention), and *P*-values for comparisons between treatment (steroid-impregnated spacers) and control (conventional management) groups. The studies were organized using a standardized format [24,25]. Outcome measures were




Fig. 1. Diagram of the study selection process.

post-treatment endoscopic findings (the Lund-Kennedy [LK] score and perioperative sinus endoscopy [POSE] score, postoperative crusting, nasal discharge, mucosal edema, ethmoid inflammation (evaluate scores with 100-mm visual analog scale by reviewers through endoscopic images; 0: no inflammation to 100: significant presence of severe inflammation), the need for oral steroid, polypoid change, and polyposis and the rate of postoperative adverse events for ESS. The definitions of terms were taken from a previous study [26]: "mucosal edema" refers to edema in areas where the bony contour is difficult to distinguish, "polypoid change" to outpouching filling the ethmoid cavity, and "polyposis" to polyp formation and growth beyond the middle meatus. The outcomes were compared between the treatment and control groups [7-23]. Quality assessment of the included randomized controlled studies was conducted using the Cochrane risk of bias tool. The Newcastle-Ottawa Scale was used to assess non-randomized controlled studies.

Statistical analysis

Meta-analyses were conducted using R software ver. 4.2.2 (R Foundation for Statistical Computing). Continuous variables were analyzed according to the standardized mean difference; odds ratios (ORs) were generated in all other cases. Heterogeneity was assessed by the I² statistic (0, no heterogeneity across studies; 100, maximum heterogeneity). All results are reported with 95% confidence intervals (CIs), and all P-values were two-tailed. When significant heterogeneity among outcomes was found (I² \geq 50), the random-effects model of DerSimonian-Laird was used. This model assumes that treatment effects may differ among studies, and that the data are normally distributed. For outcomes showing no significant heterogeneity ($I^2 < 50$), a fixed-effects model using the inverse variance approach was employed, in which it is assumed that all studies are based on the same population. Sensitivity analyses were also conducted to assess the effect of each study on the overall results of the meta-analysis.

RESULTS

In total, 16 of the 1,274 identified articles were included. The study characteristics are listed in Supplementary Tables 2, and the bias assessment results are presented in Supplementary Tables 3. Because the number of included studies was not sufficient (<10) to generate an adequate funnel plot or perform advanced regression analyses for all outcomes, publication bias was not evaluated.

Treatment and control group scores

The LK and POSE scores were significantly lower in the steroidimpregnated spacer group at 2–3 weeks (–1.1495; 95% CI, –1.8207 to 0.4783; I^2 =87.8%; P=0.0008 and –1.7656; 95% CI, –3.0236 to 0.5075; I^2 =91.8%; P=0.0060, respectively) and 2–3 months postoperatively (–0.9597; 95% CI, –1.6491 to 0.2702; $l^2=90.2\%$; *P*=0.0064 and –0.9602; 95% CI, –1.6442 to 0.2762; $l^2=91.0\%$; *P*=0.0059, respectively) than in the control group (Fig. 2A-D).

The degree of postoperative crusting at 2-3 weeks postoperatively (-0.4188; 95% CI, -0.6575 to 0.1802; I²=0.0%; P=0.0006), nasal discharge at 2-3 months postoperatively (-0.3851: 95%) CI, -0.6628 to 0.1074; I²=14.5%; P=0.0066), mucosal edema at 2-3 weeks (-0.3609; 95% CI, -0.5987 to 0.1231; I²=0.0%; P=0.0029) and 2-3 months postoperatively (-0.4290; 95% CI, -0.7073 to 0.1507; I²=12.8%; P=0.0025), ethmoid inflammation at 1 month postoperatively (-0.5080; 95% CI, -0.7109 to 0.3051; I²=0.0%; P<0.0001), polypoid changes at 1 month (0.3263; 95% CI, 0.2415; 0.4408; I²=0.0%; P<0.0001) and 2-3 months (0.3021; 95% CI, 0.1697-0.5378; I²=0.0%; P< 0.0001), polyposis at 2-3 months postoperatively (-0.5226; 95% CI, -0.8958 to 0.1493; I²=28.6%; P=0.0061), and the need for oral steroid use (0.4975; 95% CI, 0.3312–0.7471; I²=0.0%; P=0.0008) were significantly lower in the steroid-impregnated spacer group than in the control group. However, there were no significant between-group differences in crusting at 2-3 months postoperatively (-0.2041: 95% CI. -0.4791 to 0.0709: I²=0.0%: P=0.1458), nasal discharge at 2–3 weeks postoperatively (–0.2106; 95% CI, -0.4471 to 0.0258; I²=0.0%; P=0.0809), or polyposis at 2-3 weeks postoperatively (-0.2750; 95% CI, -0.5629 to 0.0128; I²=0.0%; P=0.0611) (Fig. 2E-P).

Postoperative adverse outcomes: comparison between the treatment and control groups

The steroid-impregnated spacer group showed significantly lower rates of middle turbinate lateralization (0.3887; 95% CI, 0.1835–0.8233; $I^2=0.0\%$; P=0.0136), non-medical or -surgical postoperative therapeutic interventions (0.3358; 95% CI, 0.2505–0.4501; $I^2=38.2\%$; P<0.0001), and lysis of adhesions (0.3259; 95% CI, 0.2350–0.4519; $I^2=41.0\%$; P=0.0001) than the control group. Although the rates of adhesion at 2 weeks (0.7788; 95% CI, 0.2589–2.3422; $I^2=0.0\%$; P=0.6563), and scarring/synechia at 2–3 weeks (-0.2752; 95% CI, -0.5697 to 0.0193; $I^2=0.0\%$; P=0.0670) did not differ between the groups postoperatively, there was a difference in adhesions at 1 month (0.3179; 95% CI, 0.1911–0.5290; $I^2=0.0\%$; P<0.0001) and both adhesions (0.2882; 95% CI, 0.1451-0.5724; $I^2=0.0\%$; P=0.0004) and scarring/synechia (-0.3326; 95% CI, -0.6225 to 0.0426; $I^2=0.0\%$; P=0.0246) at 2–3 months postoperatively (Fig. 3).

Subgroup analysis comparing the incidence of postoperative outcomes between the absorbable nasal dressing and drug-eluting sinus stent groups

A comparative analysis was possible between absorbable nasal dressing and drug-eluting sinus stent groups for the adhesion and polypoid change items, which are important for the prognosis after ESS. The subgroup analysis results showed no significant

	Study	Total	Exper Mean	rimental SD	Total	Mean	Control SD	s	tandard Diffe	ised Me rence	an	SMD	95	%-CI	Weight (fixed)	
	g = Absorbable nasal d								11							
	Cote 2010	18		1.0000	18	2.88	1.2500		- 1	1			[-1.44; -		9.5%	1
	Rudmik 2012 Xu 2016	18 28	3.30 2.20	1.6000 0.2000		3.10 3.30	1.6000 0.3000						[-0.53; [-5.18; -		10.3% 4.9%	1
	Zhao 2018	16	2.20	0.2000		2.81				-			[-0.49;		4.9 <i>%</i> 9.1%	1
	Zhao 2018	16	2.94	0.6000		2.77			4	ſ.			[-1.26;		8.8%	1
	Zhao 2018	17	2.47	0.3500		2.59			-				[-1.97; -		8.0%	
	Zhao 2018	15	1.66	0.3800		2.60			_						5.4%	
	Grzeskowiak 2019	40	0.58	0.8890		0.97			- i i i i i i i i i i i i i i i i i i i	4			[-2.94; - [-0.80;		22.5%	1
	Fixed effect model	168	0.56	0.0090	170	0.97	1.2190			1			[-0.98; -(78.5%	
	Random effects model				170								[-1.88; -		10.070	8
	Heterogeneity: $I^2 = 91\%$, τ^2		73. p < (0.01					T			-1.00	[-1.00, -	0.20]		
	rictorogeneity. r = 0170, t	1.20	10, p - 1	0.01												
	g = Drug-eluting sinus :															
	Murr 2011		12.00	17.3000		17.50	22.5000			1			[-0.72;			
	Fixed effect model	38			38				10	ĵ			[-0.72; 0		21.5%	
	Random effects model Heterogeneity: not applicab	ole								Í		-0.27	[-0.72;	0.18]		1
	receregeneny: net appread															
	Fixed effect model Random effects model	206			208				*				[-0.85; -		100.0%	10
	Heterogeneity: $I^2 = 90\%$, τ^2		53. p < (0.01						 		-0.90	[-1.65; -	0.27]		
	Residual heterogeneity: 12 :							-4	-2	0 2	4					
2			Exper	rimental			Control	s	standard	ised Me	an				Weight	W
	Study	Total	Mean	SD	Total	Mean	SD			rence		SMD	959	%-CI	(fixed)	
	g = Absorbable nasal d			1.0000	10	2.00	1.2500					0.76	L1 44: 4	0 001	0.6%	
	Cote 2010 Budmik 2012	18				2.88				1			[-1.44; -0		9.5%	
	Rudmik 2012	18	3.30	1.6000		3.10		_	10				[-0.53; 0		10.3%	
	Xu 2016	28	2.20	0.2000		3.30				_			[-5.18; -		4.9%	
	Zhao 2018	16	2.94	0.7700		2.81			15				[-0.49; 0		9.1%	
	Zhao 2018	16	2.47	0.6000		2.77				T			[-1.26; (8.8%	
	Zhao 2018	17				2.59							[-1.97; -		8.0%	
	Zhao 2018	15	1.66	0.3800		2.60							[-2.94; -		5.4%	
	Grzeskowiak 2019	40	0.58	0.8890		0.97	1.2190			1			[-0.80; (22.5%	
	Fixed effect model	168			170				1				[-0.98; -0		78.5%	
	Random effects model Heterogeneity: $I^2 = 91\%$, τ^2		73 n <	0.01								-1.06	[-1.88; -(0.25]		8
			15, p < 1	0.01												
	g = Drug-eluting sinus Murr 2011		12 00	17.3000	38	17 50	22.5000		1	1		-0 27	[-0.72; (0 181	21.5%	
	Fixed effect model	38	12.00		38		22.0000		- 10 E	1						
									1	*		-0.27	[-0.72: (0.181	21.5%	
	Random effects model								<u>v-v</u>	\$			[-0.72; ([-0.72; (21.5%	1
	Random effects model Heterogeneity: not applicab								¥-V	*			[-0.72; ([-0.72; (21.5%	1
	Heterogeneity: not applicab	ole 206			208				¥-V			-0.27 -0.64	[-0.72; (0.18] 0.43]		
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: $l^2 = 90\%$, τ^2	206 2 = 0.98	53, p < 0	0.01	208							-0.27 -0.64	[-0.72; (0.18] 0.43]		
	Heterogeneity: not applicab Fixed effect model Random effects model	206 2 = 0.98	p < 0.01	I	208		Control	-4	_	0 2	4	-0.27 -0.64	[-0.72; (0.18] 0.43]	 100.0% 	10
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: $l^2 = 90\%$, τ^2	206 ² = 0.98 = 91%,	p < 0.01	i imental	208 Total		Control SD	-4 St	-2 andardi	sed Mea	4	-0.27 -0.64	[-0.72; ([-0.85; -([-1.65; -(0.18] 0.43] 0.27]		10 W
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: / ² = 90%, τ ² Residual heterogeneity: / ² : Study g = Absorbable nasal d	206 2 = 0.98 = 91%, Total dressir	p < 0.01 Experi Mean	imental SD	Total	Mean	SD	-4 St	andardi	sed Mea	4	-0.27 -0.64 -0.96 SMD	[-0.72; ([-0.85; -([-1.65; -(95%	0.18] 0.43] 0.27] %-CI	 100.0% Weight (fixed)	1(V (rar
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, τ ² Residual heterogeneity: <i>I</i> ² : Study g = Absorbable nasal d Cote 2010	206 2 = 0.98 = 91%, Total dressir 19	<i>p</i> < 0.01 Experi Mean 19 4.60	imental SD	Total	Mean 6.84	SD 2.0000	-4 St	andardi	sed Mea	4	-0.27 -0.64 -0.96 SMD -1.17	[-0.72; ([-0.85; -([-1.65; -(95% [-1.86; -0	0.18] 0.43] 0.27] %-CI	 100.0% Weight (fixed) 18.3%	(ran
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, τ ² Residual heterogeneity: <i>I</i> ² : Study g = Absorbable nasal d Cote 2010 Zhao 2018	206 2 = 0.98 = 91%, Total dressir 19 16	<i>p</i> < 0.01 Experi Mean 4.60 4.94	imental SD 1.7500 0.8500	Total 19 16	6.84 6.81	SD 2.0000 0.6600	-4 St	andardi	sed Mea	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40	[-0.72; ([-0.85; -4 [-1.65; -4 959 [-1.86; -0 [-3.33; -1	0.18] 0.43] 0.27] %-CI 0.47] 1.46]	 100.0% Weight (fixed) 18.3% 10.1%	10 W (ran
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: / ² = 90%, τ ² Residual heterogeneity: / ² : Study g = Absorbable nasal d Cote 2010 Zhao 2018 Zhao 2018	206 2 = 0.98 = 91%, Total dressir 19 16 15	<i>p</i> < 0.01 Experi Mean 4.60 4.94 4.60	imental SD 1.7500 0.8500 0.6300	Total 19 16 15	6.84 6.81 6.87	SD 2.0000 0.6600 0.6400 -	-4 St	andardi	sed Mea	4 1 n	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48	[-0.72; ([-0.85; -4 [-1.65; -4 95% [-1.86; -0 [-3.33; -1 [-4.66; -2	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29]	 100.0% Weight (fixed) 18.3% 10.1% 6.3%	10 W (ran
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, τ ² Residual heterogeneity: <i>I</i> ² : Study g = Absorbable nasal d Cote 2010 Zhao 2018 Zhao 2018 Gyawali 2019	206 2 = 0.98 = 91%, Total dressir 19 16 15 58	<i>p</i> < 0.01 Experi Mean 4.60 4.94 4.60 1.21	imental SD 1.7500 0.8500	Total 19 16 15 58	6.84 6.81 6.87	SD 2.0000 0.6600	-4 St	andardi Differ	sed Mea	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37	[-0.72; ([-0.85; -4 [-1.65; -0 959 [-1.86; -0 [-3.33; -1 [-4.66; -2 [-0.73; (0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.00]	 100.0% Weight (fixed) 18.3% 10.1% 6.3%	10 W (ran
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, <i>t</i> ² Residual heterogeneity: <i>I</i> ² : Study g = Absorbable nasal of Cote 2010 Zhao 2018 Zhao 2018 Gyawali 2019 Fixed effect model	206 2 = 0.98 = 91%, Total dressir 19 16 15 58 108	<i>p</i> < 0.01 Experi Mean 4.60 4.94 4.60 1.21	imental SD 1.7500 0.8500 0.6300	Total 19 16 15	6.84 6.81 6.87	SD 2.0000 0.6600 0.6400 -	-4 St	andardi	sed Mea	4 an	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91	[-0.72; ([-0.85; -4 [-1.65; -4 95% [-1.86; -4 [-3.33; -1 [-4.66; -2 [-0.73; ([-0.73; ([-1.21; -0	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.00] 0.62]	 100.0% Weight (fixed) 18.3% 10.1% 6.3%	10 W (ran
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: /² = 30%, -?? Residual heterogeneity: /² = Study g = Absorbable nasal of Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model	206 2 = 0.98 = 91%, Total dressir 19 16 15 58 108	<i>p</i> < 0.01 Experi Mean 4.60 4.94 4.60 1.21	imental SD 1.7500 0.8500 0.6300 2.0000	Total 19 16 15 58	6.84 6.81 6.87	SD 2.0000 0.6600 0.6400 -	-4 St	andardi Differ	sed Mea	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91	[-0.72; ([-0.85; -4 [-1.65; -0 959 [-1.86; -0 [-3.33; -1 [-4.66; -2 [-0.73; (0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.00] 0.62]	 100.0% Weight (fixed) 18.3% 10.1% 6.3%	10 W (rar
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, <i>t</i> ² Residual heterogeneity: <i>I</i> ² : Study g = Absorbable nasal of Cote 2010 Zhao 2018 Zhao 2018 Gyawali 2019 Fixed effect model	206 2 = 0.98 = 91%, Total dressir 19 16 15 58 108	<i>p</i> < 0.01 Experi Mean 4.60 4.94 4.60 1.21	imental SD 1.7500 0.8500 0.6300 2.0000	Total 19 16 15 58	6.84 6.81 6.87	SD 2.0000 0.6600 0.6400 -	-4 St	andardi Differ	sed Mea	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91	[-0.72; ([-0.85; -4 [-1.65; -4 95% [-1.86; -4 [-3.33; -1 [-4.66; -2 [-0.73; ([-0.73; ([-1.21; -0	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.00] 0.62]	 100.0% Weight (fixed) 18.3% 10.1% 6.3%	1(V (rar
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: /² = 30%, -?? Residual heterogeneity: /² = Study g = Absorbable nasal of Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model	206 2 = 0.98 = 91%, Total dressir 19 16 15 58 108	<i>p</i> < 0.01 Experi Mean 4.60 4.94 4.60 1.21 688, <i>p</i> <	imental SD 1.7500 0.8500 0.6300 2.0000	Total 19 16 15 58	6.84 6.81 6.87	SD 2.0000 0.6600 0.6400 -	-4 St	andardi Differ	sed Mea	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77	[-0.72; ([-0.85; -4 [-1.65; -4 95% [-1.86; -4 [-3.33; -1 [-4.66; -2 [-0.73; ([-0.73; ([-1.21; -0	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.00] 0.62] 0.51]	 100.0% Weight (fixed) 18.3% 10.1% 63.3% 65.3% 100.0%	10 W (rar
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, <i>z</i> ² Residual heterogeneity: <i>I</i> ² : Study g = Absorbable nasal d Cote 2010 Zhao 2018 Zhao 2018 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Random effects model	206 2 = 0.98 = 91%, Total dressir 19 16 155 58 108 2 = 1.46 108	<i>p</i> < 0.01 Experi Mean 4.60 4.94 4.60 1.21 588, <i>p</i> <	imental SD 1.7500 0.8500 0.6300 2.0000 0.01	Total 19 16 15 58 108	6.84 6.81 6.87	SD 2.0000 0.6600 0.6400 -	-4 St	andardi Differ	sed Mea	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 -0.91	[-0.72; ([-0.85; -4 [-1.65; -4 959 [-1.86; -0 [-3.33; -1 [-4.66; -2 [-0.73; ([-1.21; -0 [-3.02; -0	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.26] 0.00] 0.62] 0.51]	 100.0% Weight (fixed) 18.3% 10.1% 63.3% 65.3% 100.0%	1(V (rar 1(
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 09%, <i>z</i> ² Residual heterogeneity: <i>I</i> ² Study g = Absorbable nasal of Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Heterogeneity: <i>I</i> ² = 92%, <i>z</i> ² Fixed effect model Random effects model R	206 2 = 0.98 = 91%, Total dressir 19 16 55 58 108 108 108	<i>p</i> < 0.01 Experi Mean 4.60 4.94 4.60 1.21 588, <i>p</i> <	imental SD 1.7500 0.8500 0.6300 2.0000 0.01	Total 19 16 15 58 108	6.84 6.81 6.87	SD 2.0000 0.6600 0.6400 -	, , , , , , , , , , , , , , , , , , ,	andardi Differ	sed Mea ence		-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 -0.91	[-0.72; ([-0.85; -4 [-1.66; -4 [-1.86; -4 [-3.33; -1 [-4.66; -2 [-0.73; ([-1.21; -0 [-1.21; -0 [-1.21; -0	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.26] 0.00] 0.62] 0.51]	 100.0% Weight (fixed) 18.3% 10.1% 63.3% 65.3% 100.0%	1(V (rar 1(
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, <i>z</i> ² Residual heterogeneity: <i>I</i> ² : Study g = Absorbable nasal d Cote 2010 Zhao 2018 Zhao 2018 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Random effects model	206 2 = 0.98 = 91%, Total dressir 19 16 55 58 108 108 108	<i>p</i> < 0.01 Experi Mean 4.60 4.94 4.60 1.21 588, <i>p</i> < 588, <i>p</i> < 588, <i>p</i> < 0.0	1.7500 0.8500 0.6300 2.0000 0.01 0.01	Total 19 16 15 58 108	6.84 6.81 6.87 1.95	SD 2.0000 0.6600 0.6400 2.0000	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 -0.91	[-0.72; ([-0.85; -4 [-1.66; -4 [-1.86; -4 [-3.33; -1 [-4.66; -2 [-0.73; ([-1.21; -0 [-1.21; -0 [-1.21; -0	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.26] 0.00] 0.62] 0.51]	 100.0% (fixed) 18.3% 10.1% 65.3% 100.0% 100.0% 	1(V (rar 1(
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 09%, <i>z</i> ² Residual heterogeneity: <i>I</i> ² Study g = Absorbable nasal of Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Heterogeneity: <i>I</i> ² = 92%, <i>z</i> ² Fixed effect model Random effects model R	206 206 206 20 20 20 20 20 20 20 20	<i>p</i> < 0.01 Experi Mean 4.60 4.94 4.60 1.21 588, <i>p</i> < 588, <i>p</i> < 588, <i>p</i> < 0.0	1.7500 0.8500 0.6300 2.0000 0.01 1 imental	Total 19 16 15 58 108	Mean 6.84 6.81 6.87 1.95	SD 2.0000 0.6600 0.6400 -	-4	andardi Differ	sed Mea ence	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 -0.91	[-0.72; ([-0.85; -4 [-1.65; -4 [-1.86; -6 [-3.33; -1 [-4.66; -2 [-0.73; ([-1.21; -0 [-1.21; -0 [-3.02; -0	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.00] 0.62] 0.51]	 100.0% Weight (fixed) 18.3% 10.1% 63.3% 65.3% 100.0%	1(V (rar 1(1(
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: $l^2 = 90\%, z^2$ Study g = Absorbable nasal of Cote 2010 Zhao 2018 Zhao 2018 Zhao 2018 Cayawaii 2019 Fixed effect model Random effects modell Heterogeneity: $l^2 = 92\%, z^2$ Fixed effect model Heterogeneity: $l^2 = 92\%, z^2$ Study g = Absorbable nasal of Study g = Absorbable nasal of Study	206 206 2 = 0.98 91%, Total dressir 19 16 158 58 58 108 108 108 108 108 108 108 108 108 10	<i>p</i> < 0.01 Experi Mean 19 4.60 4.94 4.60 1.21 588, <i>p</i> < 588, <i>p</i> < 588, <i>p</i> < 0.00 Experi	imental SD 1.7500 0.8500 0.6300 2.0000 0.01 0.01 1 imental SD	Total 19 16 15 58 108 108 108	Mean 6.84 6.81 6.87 1.95 Mean	SD 2.0000 0.6600 2.0000 2.0000	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 -0.91 -1.77 SMD	[-1.86; -4 959 [-1.86; -4 [-3.33; -1 [-4.66; -2 [-0.73; (-1 [-3.02; -C [-1.21; -6]] [-1.21; -6]] [-2.21; -6]]\\[-2.21; -6]]\\[-2.21; -6]]\\[-2.21; -6]]\\[-2.21; -6]]\\[-2.21; -6]]\\[-2.21; -6]]\\[-2.21; -6]]	0.18] 0.43] 0.27] %-CI 0.47] 1.46] 2.29] 0.00] 0.62] 0.51] 0.51] 0.51]	 100.0% - Weight (fixed) 18.3% 10.1% 65.3% 100.0% 100.0% Weight (fixed)	1(V (rar 1) 1(W (rar
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: P^2 90%, r^2 Residual heterogeneity: P^2 Study g = Absorbable nasal of Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: P^2 92%, r^2 Fixed effect model Random effects model Heterogeneity: P^2 92%, r^2 Study g = Absorbable nasal of Cote 2010	206 206 2 = 0.98 91%, Total dressir 19 16 55 58 108 2 = 1.46 108 2 = 1.46 108 2 = 92%, Total	p < 0.01 Experi Mean 19 4.60 4.94 4.60 1.21 388, $p < 4.60$ 388, $p < 0.0$ Experi Mean	imental SD 1.7500 0.8500 0.6300 2.0000 0.01 0.01 1 imental SD 2.7500	Total 19 16 15 58 108 108 108 Total	Mean 6.84 6.81 6.87 1.95 Mean 5.72	SD 2.0000 0.6600 2.0000 2.0000 Control SD 2.7500	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 SMD -0.91 -0.43	[-0.72; ([-0.85; -4] [-1.65; -4] 959 [-1.86;6] [-3.33; -1] [-4.66; -2] [-3.33; -1] [-4.66; -2] [-3.33; -1] [-4.66; -2] [-4.73; -6] [-4.74], -6] [-5.74], -6] [-7.74], -6]\\	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.00] 0.62] 0.62] 0.51] 0.62] 0.51]	 100.0% URE (fixed) 18.3% 10.1% 65.3% 100.0% 100.0% URE (fixed) 8.7%	1(W (rar 1(1(W (ran
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, ² Residual heterogeneity: <i>I</i> ² : Study g = Absorbable nasal d Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, ² Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, ² Residual heterogeneity: <i>I</i> ² Study g = Absorbable nasal d Cote 2010 More 2011	206 206 7 Total 19 16 158 58 108 108 2 = 1.46 108 108 2 = 92%, Total 108 2 = 92%, Total 2 = 1.46 2 = 92%, 108 2 = 92%, 108 2 = 92%, 108 2 = 92%, 108 2 = 91%, 108 2 = 92%, 108 2 = 92%, 108%, 1	p < 0.01 Experi Mean 19 4.60 1.21 388, $p < 0.0$ Experi Mean 1.21 388, $p < 0.0$ Experi Mean 1.21 388, $p < 0.01$ 388, $p < 0.01$ 389, $p < 0.01$ 399, $p < 0.01$ 390,	imental SD 1.7500 0.8500 0.6300 2.0000 0.01 0.01 1 imental SD 2.7500 3.2500	Total 19 16 15 58 108 108 108 Total 18 21	Mean 6.84 6.81 6.87 1.95 Mean 5.72 5.52	SD 2.0000 0.6600 2.0000 2.0000 Control SD 2.7500 3.0000	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 -0.91 -1.77 SMD -0.43 0.16	[-1.22; (-1.22; -1.22;	0.18] 0.43] 0.27] %-CI 0.47] 1.46] 2.29] 0.00] 0.62] 0.62] 0.51] 0.62] 0.51]	 100.0% Weight (fixed) 18.3% 101.0% 65.3% 100.0% 100.0% Weight (fixed) 8.7% 10.1%	1(W (rar 1(1(W (ran
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, <i>z</i> ² Residual heterogeneity: <i>I</i> ² Study g = Absorbable nasal of Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, <i>z</i> ² Fixed effect model Random effects model R	206 2 = 0.98 2 = 0.98 2 = 0.98 108 108 108 108 108 108 108 10	p < 0.01 Experim Mean 19 4.60 4.94 4.60 1.21 388, $p < 0.0$ Experim Mean 9 Experim Mean 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 Experim 10 10 10 10 10 10 10 10 10 10	1.7500 0.8500 2.0000 0.01 1 1 1 2.7500 3.2500 0.800	Total 19 16 58 108 108 Total 18 21 30	Mean 6.84 6.81 1.95 Mean 5.72 5.52 7.00	SD 2.0000 0.6600 2.0000 2.0000 2.0000 2.0000 2.7500 3.0000 1.0000	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 SMD -0.91 -1.77 SMD	[-1.72; ([-0.85; 4] [-1.86; -4] [-1.86; -4] [-1.86; -4] [-1.86; -2] [-1.86; -2] [-1.21; -2] [-1.21; -2] [-1.21; -2] [-1.21; -2] [-1.21; -2] [-1.21; -2] [-2.21; -	0.18] 0.43] 0.27] %-CI 0.27] 1.46] 2.29] 0.00] 0.62] 0.51] 0.62] 0.51] 0.51] 0.51] 0.51]	 100.0% Weight (fixed) 18.3% 10.1% 65.3% 100.0% 100.0% Weight (fixed) 8.7% 10.7% 7.2%	1(W (rar 1(1(VM (ran
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, <i>z</i> ² Residual heterogeneity: <i>I</i> ² = Study g = Absorbable nasal of Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, <i>z</i> ² Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, <i>z</i> ² Study g = Absorbable nasal of Cote 2010 More 2011 Xu 2016 Hwang 2017	206 2 = 0.98 2 = 0.91%, Total dressir 19 16 158 108 2 = 1.46 108 2 = 1.46 108 2 = 1.46 108 2 = 0.92%, Total 18 20 2 8 2 10 10 10 10 10 10 10 10 10 10	p < 0.01 Experi Mean 19 4.60 4.94 4.60 1.21 388, $p < 0.01$ 388, $p < 0.01$ Experi Mean 10 4.50 6.04 4.50 6.04 4.50 6.04 4.50 6.04 4.50 6.04 4.50 6.04 4.50 6.04 4.50 6.04 4.50 6.04 4.50 6.05	1.7500 0.8500 0.03000 0.01 0.01 1 1 2.7500 0.2000 0.8000 0.3.2500	Total 19 16 15 58 108 108 Total 18 21 30 022	Mean 6.84 6.81 6.87 1.95 Mean 5.72 5.52 7.00 7.71	SD 2.0000 0.6400 2.0000 2.0000 2.7500 3.0000 1.0000 4.0400	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 -0.91 -1.77 SMD -0.43 0.16 -2.71 -0.82	[-0.72; (-0.72; (-0.72; (-0.72; (-0.72; (-0.72; (-0.72; (-0.72; (-0.73	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.62] 0.551] 0.62] 0.551] 0.62] 0.551] 0.62] 0.551]	 100.0% Weight 18.3% 10.1% 65.3% 100.0% 100.0% Weight (fixed) 8.7% 10.1% 7.2% 10.0%	1(W (rar 1(1((ran
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, τ ² Residual heterogeneity: <i>I</i> ² : Study g = Absorbable nasal d Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, τ ² Fixed effect model Heterogeneity: <i>I</i> ² = 92%, τ ² Study g = Absorbable nasal d Cote 2010 More 2011 Xu 2016 Hwang 2017 Zhao 2018	206 2 = 0.98 2 = 0.98 2 = 0.98 10 10 10 10 10 15 58 10 10 10 10 10 10 10 10 10 10	p < 0.01 Experim Mean 4.60 4.94 4.60 1.21 388, $p < 0.0$ Experim Mean 19 4.50 6.04 4.60 4.65 3.06	1 imental SD 1.7500 0.8500 0.0300 2.0000 0.01 1 imental SD 2.7500 3.2500 0.8000 0.8000 0.8000 0.8000 0.8500 0.8500 0.01 1 1 1 1 1 1 1 1 1 1 1 1 1	Total 19 16 58 108 108 Total 18 21 30 02 16	Mean 6.84 6.81 6.87 1.95 Mean 5.72 5.52 7.00 7.71 3.25	SD 2.0000 0.6400 2.0000 2.0000 2.0000 2.7500 3.0000 1.0000 4.0400 0.6800	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 -0.91 -1.77 SMD -0.43 0.16 -2.71 -0.27	[-0.72; ([-0.85; 4 [-1.86; -0. [-3.33; -1] [-4.66; -2] [-4.66; -2] [-4.72; -0] [-4.72; -0] [-4.72; -0] [-4.72; -0] [-4.72; -0] [-1.42; -0] [-1.44; -0] [-1.44] [-1.44; -0] [-1.44] [-1.44; -0] [-1.44	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.00] 0.62] 0.51] 0.62] 0.51] 0.62] 0.51] 0.62] 0.51]	 100.0% - Weight (fixed) 18.3% 101.0% 65.3% 100.0% 100.0% Weight (fixed) 8.7% 10.1% 7.2% 10.0% 7.9%	1(w(rar 1(1(w(ran
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: /² = 90%, -² Residual heterogeneity: /² = Study g = Absorbable nasal d Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: /² = 92%, -² Fixed effect model Random effects model Heterogeneity: /² = 92%, -² Residual heterogeneity: /² Study g = Absorbable nasal d Cote 2010 More 2011 Xu 2016 Hwang 2017 Zhao 2018 Chao 2018	206 2 = 0.98 = 91%, Total dressir 10 10 12 = 1.46 10 10 10 10 10 10 10 10 10 10	p < 0.01 Experi Mean 4.60 4.94 4.60 1.21 1.21 388, $p < 0.0$ Experi Mean 9 4.50 6.04 4.50 5.306 2.94	imental SD 1.7500 0.8500 0.6300 2.0000 0.011 1 imental SD 2.7500 0.8800 0.6800 0.6800 0.6700	Total 19 15 58 108 108 Total 18 21 30 22 16 16 16	Mean 6.84 6.81 6.87 1.95 5.72 5.52 7.00 7.71 3.25 3.06	SD 2.0000 0.6600 2.0000 2.0000 2.7500 3.0000 1.0000 4.0400 0.8500	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 SMD -0.43 0.16 -2.71 -0.27 -0.27 -0.16	[-0.72; ([-0.85; 4] [-1.65; 4] [-1.65; 4] [-1.66; 4] [-1.66; 2] [-1.06; 2] [-1.07; 4] [-1.02; -0] [-1.01; 4] [-1.02; 4]	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 0.00] 0.62] 0.51] 0.62] 0.51] 0.62] 0.51] 0.62] 0.51]	 100.0% Weight (fixed) 18.3% 10.1% 65.3% 100.0% 100.0% Weight (fixed) 8.7% 10.1% 7.2% 10.0% 7.9%	1(W (rar 1(1((ran
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, τ ² Residual heterogeneity: <i>I</i> ² : Study g = Absorbable nasal d Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, τ ² Fixed effect model Heterogeneity: <i>I</i> ² = 92%, τ ² Study g = Absorbable nasal d Cote 2010 More 2011 Xu 2016 Hwang 2017 Zhao 2018	206 2 = 0.98 2 = 0.98 2 = 0.98 10 10 10 10 10 15 58 10 10 10 10 10 10 10 10 10 10	p < 0.01 Experi Mean 4.60 4.94 4.60 1.21 1.21 388, $p < 0.0$ Experi Mean 9 4.50 6.04 4.50 5.306 2.94	1 imental SD 1.7500 0.8500 0.0300 2.0000 0.01 1 imental SD 2.7500 3.2500 0.8000 0.8000 0.8000 0.8000 0.8500 0.8500 0.01 1 1 1 1 1 1 1 1 1 1 1 1 1	Total 19 16 58 108 108 Total 18 21 30 02 16	Mean 6.84 6.81 6.87 1.95 5.72 5.52 7.00 7.71 3.25 3.06	SD 2.0000 0.6400 2.0000 2.0000 2.0000 2.7500 3.0000 1.0000 4.0400 0.6800	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 SMD -0.43 0.16 -2.71 -0.27 -0.27 -0.16	[-0.72; ([-0.85; 4 [-1.86; -0. [-3.33; -1] [-4.66; -2] [-4.66; -2] [-4.72; -0] [-4.72; -0] [-4.72; -0] [-4.72; -0] [-4.72; -0] [-1.42; -0] [-1.44; -0] [-1.44] [-1.44; -0] [-1.44] [-1.44; -0] [-1.44	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 0.00] 0.62] 0.51] 0.62] 0.51] 0.62] 0.51] 0.62] 0.51]	 100.0% - Weight (fixed) 18.3% 101.0% 65.3% 100.0% 100.0% Weight (fixed) 8.7% 10.1% 7.2% 10.0% 7.9%	1(v (rar 1) (rar
	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: /² = 90%, -² Residual heterogeneity: /² = Study g = Absorbable nasal d Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: /² = 92%, -² Fixed effect model Random effects model Heterogeneity: /² = 92%, -² Residual heterogeneity: /² Study g = Absorbable nasal d Cote 2010 More 2011 Xu 2016 Hwang 2017 Zhao 2018 Chao 2018	206 2 = 0.98 = 91%, Total dressir 10 10 12 = 1.46 10 10 10 10 10 10 10 10 10 10	p < 0.01 Experimentary for the second sec	imental SD 1.7500 0.8500 0.6300 2.0000 0.011 1 imental SD 2.7500 0.8800 0.6800 0.6800 0.6700	Total 19 15 58 108 108 Total 18 21 30 22 16 16 16	Mean 6.84 6.81 6.87 1.95 Mean 5.72 5.52 7.00 7.71 3.25 3.06 2.94	SD 2.0000 0.6600 2.0000 2.0000 2.7500 3.0000 1.0000 4.0400 0.8500	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.91 -1.77 -0.91 -1.77 SMD -0.43 0.16 -2.71 -0.82 -0.27 -0.18	[-0.72; ([-0.85; 4] [-1.65; 4] [-1.65; 4] [-1.66; 4] [-1.66; 2] [-1.06; 2] [-1.07; 4] [-1.02; -0] [-1.01; 4] [-1.02; 4]	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.62] 0.51] 0.62] 0.51] 0.78] 0.78] 0.23] 0.78] 1.99] 0.21] 0.42] 0.23]	 100.0% Weight (fixed) 18.3% 10.1% 65.3% 100.0% 100.0% Weight (fixed) 8.7% 10.1% 7.2% 10.0% 7.9%	1(W (rar 1(1((ran
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, τ ² Residual heterogeneity: <i>I</i> ² = Study g = Absorbable nasal of Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, τ ² Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, τ ² Study g = Absorbable nasal of Cote 2010 More 2011 Xu 2016 Hwang 2017 Zhao 2018 Zhao 2018 Zhao 2018	206 2 2 0.98 = 91%, Total 19 16 58 108 108 108 102 2 1.46 108 2 1.47 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 3 3 109 3 3	p < 0.01 Experi Mean 19 4.60 4.94 4.60 1.21 388, $p < 0.0$ 588, $p < 0.0$ Exper Mean 19 4.50 4.50 4.50 4.50 5.294 2.20	imental SD 1.7500 0.8500 0.6300 2.0000 0.011 1 1 1 2.7500 3.2500 0.8000 0.8000 0.8000 0.5300	Total 19 16 15 58 108 108 108 Total 18 21 30 022 16 16 16 16 17 10 10 10 10 10 10 10 10 10 10	Mean 6.84 6.81 6.87 1.95 Mean 5.72 5.52 7.00 Mean 3.25 3.06 2.94 4.13	SD 2.0000 0.6400 2.0000 2.0000 2.7500 3.0000 1.0000 4.0400 0.8800 0.8500 0.7500	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 -0.91 -1.77 SMD -0.43 0.16 -2.71 -0.27 -0.27 -0.27 -0.27 -0.27	[-1.72; ([-0.85; 4 [-1.85; -4 [-1.86; -6] [-1.86; -6] [-3.33; -1 [-4.86; -6] [-4.86; -6] [-4.86; -6] [-4.86; -6] [-1.21; -6]	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.62] 0.51] 0.62] 0.51] 0.51] 0.51] 0.51] 0.23] 0.78] 1.99] 0.42] 0.21] 0.42] 0.42] 1.49]	 100.0% Weight 18.3% 10.0% 65.3% 100.0% 100.0% Weight (fixed) 8.7% 10.1% 7.2% 10.0% 7.9% 8.4%	1(W (rar 1(1(
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, τ ² Residual heterogeneity: <i>I</i> ² : Study g = Absorbable nasal d Cote 2010 Zhao 2018 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, τ ² Fixed effect model Heterogeneity: <i>I</i> ² = 92%, τ ² Study g = Absorbable nasal d Cote 2010 More 2011 Xu 2016 Hwang 2017 Zhao 2018 Zhao 2018 Zhao 2018 Zhao 2018	206 2 2 0.98 = 91%, Total 1 1 dressir 19 16 15 58 108 108 2 = 1.46 2 = 1.42 = 92%, Total 18 2 2 1.46 dressir 18 28 22 2 16 16 16 16 16 17 15	<i>p</i> < 0.01 Experimental Second Seco	1,7500 0,8500 0,06300 2,0000 0,011 1 1 1 1 1 1 2,7500 0,8000 0,22000 0,0800 0,08000 0,05300 0,05300 0,06800	Total 19 16 15 58 108 108 Total 18 21 30 22 16 16 17 15 108	Mean 6.84 6.81 6.87 1.95 Mean 5.72 5.52 7.00 Mean 3.25 3.06 2.94 4.13	SD 2.0000 0.6600 2.0000 2.0000 2.7500 3.0000 4.0400 0.8500 0.7500 0.8300 0.8300	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 -0.91 -1.77 SMD -0.43 0.16 -0.43 0.16 2.71 -0.271 -0.16 -0.21 -0.24 -0.24 -0.24 -0.12 -0.12 -0.12 -0.12 -0.24 -0.24 -0.25 -0.24 -0.27 -0.24 -0.24 -0.24 -0.24 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.24 -0.27 -0.27 -0.27 -0.27 -0.27 -0.24 -0.27	[-1.72; ([-0.85; 4 [-1.86; -4 [-1.86; -4 [-3.33; -1 [-4.66; -2 [-3.02; -0 [-1.21; -6 [-3.02; -0 [-1.21; -6 [-3.02; -0 [-1.10; 0 [-1.41], -0 [-1.42], -0 [-1.44], -1 [-1.44], -1\\[-1.44], -1\\[-1.44], -1\\[-1.44], -1\\[-1.44], -1\\[-1.44], -1\\[-1.44], -1\\[-1.44], -1\\[-1.44],	0.18] 0.43] 0.27] %-CI 0.47] 1.46] 2.29] 0.00] 0.51] 0.62] 0.55] 0.62] 0.55] 0.62] 0.55] 0.55] 0.23] 0.23] 0.23] 0.23] 0.23] 0.242] 0.253] 0.42] 0.423] 0.423] 0.423] 0.423] 0.423] 0.423] 0.443] 0.443] 0.443] 0.443] 0.443] 0.445] 0.44	 100.0% Weight (fixed) 18.3% 101.0% 65.3% 100.0% 100.0% Weight (fixed) 8.7% 10.1% 7.2% 10.0% 7.9% 8.4%	1(W (rar 1(1(
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, <i>I</i> ² Residual heterogeneity: <i>I</i> ² Study g = Absorbable nasal of Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, <i>I</i> ² Fixed effect model Random effects model Random effects model Random effect model Random effect model Random effect model Random effect model Random effect model Random effect model Absorbable nasal of Cote 2010 More 2011 Xu 2016 Hwang 2017 Zhao 2018 Zhao 2018 Zhao 2018 Zhao 2018 Zhao 2018 Samarei 2020 Fixed effect model Random effects model	206 2 2 0.98 = 91%, Total Irressir 19 16 15 58 108 108 108 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.61 108 2 1.61 104 2 2.56 104	p < 0.01 Experi Mean 19 4.60 4.94	imental SD 1.7500 0.8500 0.6300 2.0000 0.01 1 imental SD 2.7500 0.8000 0.5700 0.6800 0.5700 0.6800 0.5300 0.5300	Total 19 16 15 58 108 108 Total 18 21 10 22 16 17 15 104	Mean 6.84 6.81 6.87 1.95 Mean 5.72 5.52 7.00 Mean 3.25 3.06 2.94 4.13	SD 2.0000 0.6600 2.0000 2.0000 2.7500 3.0000 4.0400 0.8500 0.7500 0.8300 0.8300	-4	andardii Differ	sed Mea ence	4	-0.27 -0.64 -0.96 -0.96 -0.96 -0.91 -1.77 -0.91 -0.91 -1.77 -0.91 -0.91 -0.7 -0.91 -0.7 -0.18 -0.27 -0.18 -0.27 -0.18 -0.27 -0.18 -0.27 -0.18 -0.27 -0.240 -0.96 -0.97 -0.91 -0.97 -0.91 -0.97 -0.91 -0.97 -0.91 -0.97 -0.91 -	[-0.72; ([-0.85; 4] [-1.65; 4] [-1.65; 4] [-1.66; 4] [-3.33; -1] [-3.33; -1] [-3.33; -1] [-3.33; -1] [-3.33; -1] [-4.66; 2] [-3.33; -1] [-4.66; 2] [-4.71; -0] [-4.71; -0] [-	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.62] 0.51] 0.62] 0.51] 0.62] 0.51] 0.23] 0.78] 0.23] 0.24] 0.25] 0.24] 0.24] 0.25] 0.24] 0.25] 0.24] 0.25] 0.24] 0.25] 0.2	 100.0% Weight (fixed) 18.3% 10.1% 65.3% 100.0% 100.0% Weight (fixed) 8.7% 10.1% 7.2% 10.0% 7.9% 7	1(v (rar 1) (rar
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, τ ² Residual heterogeneity: <i>I</i> ² = Study g = Absorbable nasal of Cole 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, τ ² Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, τ ² Study g = Absorbable nasal of Cole 2010 More 2011 Xu 2016 Hwang 2017 Zhao 2018 Zhao 2018	206 2 2 0.98 = 91%, Total Irressir 19 16 15 58 108 108 108 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.46 108 2 1.61 108 2 1.61 104 2 2.56 104	p < 0.01 Experi Mean 19 4.60 4.94	imental SD 1.7500 0.8500 0.6300 2.0000 0.01 1 imental SD 2.7500 0.8000 0.5700 0.6800 0.5700 0.6800 0.5300 0.5300	Total 19 16 15 58 108 108 Total 18 21 10 22 16 17 15 104	Mean 6.84 6.81 6.87 1.95 Mean 5.72 5.52 7.00 Mean 3.25 3.06 2.94 4.13	SD 2.0000 0.6600 2.0000 2.0000 2.7500 3.0000 4.0400 0.8500 0.7500 0.8300 0.8300	-4	andardii Differ	sed Mea ence		-0.27 -0.64 -0.96 -0.96 -0.96 -0.91 -1.77 -0.91 -0.91 -1.77 -0.91 -0.91 -0.7 -0.91 -0.7 -0.18 -0.27 -0.18 -0.27 -0.18 -0.27 -0.18 -0.27 -0.18 -0.27 -0.240 -0.96 -0.97 -0.91 -0.97 -0.91 -0.97 -0.91 -0.97 -0.91 -0.97 -0.91 -	[-1.86; -4 [-1.86; -4 [-1.86; -4 [-1.86; -4 [-3.33; -1 [-4.66; -2 [-3.02; -6 [-1.21; -6][-1.21] [-1.21; -6][-1.21] [-1.21; -6][-1.21] [-1.21; -6][-1.21] [-	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 2.29] 0.62] 0.55] 0.62] 0.55] 0.62] 0.55] 0.23] 0.78] 0.23] 0.24] 0.25] 0.24] 0.24] 0.25] 0.24] 0.25] 0.24] 0.25] 0.24] 0.25] 0.2	 100.0% Weight (fixed) 18.3% 10.1% 65.3% 100.0% 100.0% Weight (fixed) 8.7% 10.1% 7.2% 10.0% 7.9% 7	1(v (rar 1) (rar
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, <i>i</i> ² Residual heterogeneity: <i>I</i> ² Study g = Absorbable nasal of Cote 2010 Zhao 2018 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, <i>i</i> ² Fixed effect model Random effects model Random effects model Random effect model Tixed effect model Hwang 2011 Zhao 2018 Zhao 2018 Zhao 2018 Zhao 2018 Samarei 2020 Fixed effect model Heterogeneity: <i>I</i> ² = 91%, <i>i</i> Fixed effect model Heterogeneity: <i>I</i> ² = 91%, <i>i</i> Fixed effect model	206 2 2 0.98 = 91%, Total Irressir 19 16 15 58 108 108 108 12 108 2 1.46 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 108 2 2 100 2 2 101 2 2 102 2 106 104 2 2 104 2 2 104 2 2 104 2 2	p < 0.01 Experimental Sector 4.60 4.60 1.21 388 , $p < 4.94$ 4.60 588 , $p < 0.0$ Experimental Sector 4.50 5.60 4.50 5.60 4.50 5.60 4.50 5.60 4.50 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60 5	imental SD 1.7500 0.8500 0.6300 2.0000 0.01 1 imental SD 2.7500 0.8000 0.5700 0.6800 0.5700 0.6800 0.5300 0.5300	Total 19 16 15 58 108 108 Total 18 21 10 22 16 17 15 104	Mean 6.84 6.81 6.87 1.95 Mean 5.72 5.52 7.00 Mean 3.25 3.06 2.94 4.13	SD 2.0000 0.6600 2.0000 2.0000 2.7500 3.0000 4.0400 0.8500 0.7500 0.8300 0.8300	-4	andardii Differ	sed Mea ence		-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 SMD -0.91 -1.77 SMD -0.91 -1.77 SMD -0.91 -1.77 -0.91 -1.77 -0.91 -1.77 -0.94 -1.17 -0.94 -1.17 -0.95 -0	[-0.72; ([-0.85; 4] [-1.86; -4] [-1.86; -4] [-1.86; -4] [-3.33; -1] [-4.86; -2] [-3.33; -1] [-4.86; -2] [-3.33; -1] [-4.86; -2] [-4.71; -4] [-4.71; -4] [-4.71; -4] [-4.85; -	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 0.22] 0.00] 0.62] 0.51] 0.62] 0.51] 0.51] 0.23] 0.23] 0.23] 0.23] 0.25] 1.99] 0.21] 0.42] 0.55] 0.42] 0.42] 0.42] 0.55] 0.42] 0.42] 0.55] 0.42] 0.42] 0.42] 0.55] 0.42] 0.42] 0.42] 0.55] 0.42] 0.42] 0.42] 0.42] 0.57] 0.42] 0.4	 100.0% - Weight (fixed) 18.3% 101.0% 65.3% 100.0% - 100.0% - Weight (fixed) 8.7% 101.0% 7.2% 10.1% 7.2% 10.1% 5.3% 10.1% 0.1% 10.1% 5.3% 10.1% - Weight (fixed) - - - - - - - - - - - -	1(W (rar 1(1(
•	Heterogeneity: not applicab Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 90%, τ ² Residual heterogeneity: <i>I</i> ² = Study g = Absorbable nasal c Cote 2010 Zhao 2018 Gyawaii 2019 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, τ ² Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 92%, τ ² Study g = Absorbable nasal c Cote 2010 More 2011 Xu 2016 Hwang 2017 Zhao 2018 Zhao	206 2 2 0.98 = 91%, 19 Total 19 16 15 58 108 108 2 1.46 108 2 1.46 108 2 1.46 108 2 2 108 2 2 108 2 2 104 2 2 105 2 1.46 102 2 1.46 102 2 1.46 104 2 1.67 104 2 1.67 104 2 1.66 106 1.77 1.57 104 2 2 0.97 2 2 0.97 2	p < 0.01 Experimental Sector Mean 19 4.600 4.94 4.600 1.21 388, $p < 0.01$ 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50	imental SD 1.7500 0.8500 0.6300 2.0000 0.011 1 imental SD 0.8000 0.8000 0.8000 0.8000 0.5700 0.6800 0.5700 0.5300 0.0570000000000	Total 19 16 15 58 108 108 Total 18 21 30 02 216 16 17 15 104 259	Mean 6.84 6.81 6.87 1.95 Mean 5.72 5.52 7.00 Mean 3.25 3.06 2.94 4.13	SD 2.0000 0.6600 2.0000 2.0000 2.7500 3.0000 4.0400 0.8500 0.7500 0.8300 0.8300	-4	andardii Differ	sed Mea ence		-0.27 -0.64 -0.96 SMD -1.17 -2.40 -3.48 -0.37 -0.91 -1.77 SMD -0.91 -1.77 SMD -0.91 -1.77 SMD -0.91 -1.77 -0.91 -1.77 -0.91 -1.77 -0.94 -1.17 -0.94 -1.17 -0.95 -0	[-1.86; -4 [-1.86; -4 [-1.86; -4 [-1.86; -4 [-3.33; -1 [-4.86; -2 [-3.02; -6 [-1.21; -6 [-1.21; -6 [-1.21; -6 [-1.21; -6 [-1.21; -6 [-1.21; -6 [-1.21; -6 [-1.21; -6][-1.21] [-1.41; -6 [-1.21; -6][-1.21] [-1.41; -6][-1.21] [-1.41; -6][-1.21] [-1.41; -6][-1.21] [-1.41; -6][-1.21] [-1.41; -6][-1.21] [-1.41; -6][-1.21] [-1.41; -6][-1.21] [-1.41] [-1.41] [-1.41] [-1.41] [-1.21] [-1.41] [-1.41] [-1.21] [-1.41] [-1.41] [-1.21] [-1.41] [-1.41] [-1.21] [-1.21] [-1.41] [-1.41] [-1.21	0.18] 0.43] 0.27] %-Cl 0.47] 1.46] 0.22] 0.00] 0.62] 0.51] 0.62] 0.51] 0.51] 0.23] 0.23] 0.23] 0.23] 0.25] 1.99] 0.21] 0.42] 0.55] 0.42] 0.42] 0.42] 0.55] 0.42] 0.42] 0.55] 0.42] 0.42] 0.42] 0.55] 0.42] 0.42] 0.42] 0.55] 0.42] 0.42] 0.42] 0.42] 0.57] 0.42] 0.4	 100.0% - Weight (fixed) 18.3% 101.0% 65.3% 100.0% - 100.0% - Weight (fixed) 8.7% 101.0% 7.2% 10.1% 7.2% 10.1% 5.3% 10.1% 0.1% 10.1% 5.3% 10.1% - Weight (fixed) - - - - - - - - - - - -	1(W (rar 1(1(W (ran

Fig. 2. Severity of postoperative adverse outcomes based on endoscopic examinations: comparison between the treatment and control groups. The Lund-Kennedy score at 2–3 weeks (A), and 2–3 months (B), perioperative sinus endoscopy score at 2–3 weeks (C) and 2–3 months (D). (Continued to the next page)

Ø	Study		Experimental Mean SD	Total	Control Mean SD		Standardis Differe			SMD	95%-CI		Weight (random)
	g = Absorbable nasal di Ha 2017 Ha 2017 Grzeskowiak 2019 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 =$	23 23 40 58 144	0.26 0.6190 0.26 0.6190 0.60 0.4960 0.14 0.3950	13 25 40 58 136	0.54 0.8770 0.40 0.7000 0.73 0.4520 0.50 0.7070					-0.21 -0.27 -0.63 -0.42	[-1.06; 0.31] [-0.78; 0.36] [-0.71; 0.17] [-1.00; -0.26] [-0.66; -0.18] [-0.66; -0.18]	12.1% 17.7% 29.4% 40.9% 100.0%	12.1% 17.7% 29.4% 40.9% 100.0%
	Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 =$ Residual heterogeneity: I^2	144 = 0, p = = 0%, p	= 0.54 = 0.54	136		-1	-0.5 0	0.5	1		[-0.66; -0.18] [-0.66; -0.18]	100.0% 	 100.0%
Ð	Study		Experimental Mean SD	Total	Control Mean SD		Standardis Differe			SMD			Weight (random)
	g = Absorbable nasal di Ha 2017 Ha 2017 Hwang 2017 Grzeskowiak 2019 Fixed effect model Heterogeneity: / ² = 0%, τ ² = Fixed effect model Random effects model	23 23 22 40 108	0.04 0.2080 0.04 0.2080 0.39 0.5200 0.00 0.0010	13 25 22 40 100	0.23 0.5990 0.20 0.5770 0.53 0.6800 0.00 0.0010		·····			-0.35 -0.23 0.00 -0.20 -0.20 -0.20	[-1.15; 0.22] [-0.92; 0.22] [-0.82; 0.37] [-0.44; 0.44] [-0.48; 0.07] [-0.48; 0.07] [-0.48; 0.07]	23.2% 21.5% 39.4% 100.0%	15.9% 23.2% 21.5% 39.4% 100.0%
	Heterogeneity: $l^2 = 0\%$, $\tau^2 = $ Residual heterogeneity: $l^2 = $	= 0, p = = 0%, p	= 0.65 = 0.65			-1	-0.5 0	0.5	1	-0.20	[-0.48; 0.07]		100.0%
G	Study	Total	Experimental Mean SD	Total	Control Mean SD		Standardis Differe			SMD	95%-CI		Weight (random)
	g = Absorbable nasal di Ha 2017 Ha 2017 Grzeskowiak 2019 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: I^2 = 0%, τ^2 :	23 23 40 58 144	0.13 0.4570 0.13 0.4570 0.55 0.5520 0.14 0.4372	13 25 40 58 136	0.50 0.7970 0.20 0.2000 0.65 0.6220 0.21 0.5543			 		-0.20 -0.17 -0.14 -0.21	[-1.30; 0.09] [-0.77; 0.37] [-0.61; 0.27] [-0.50; 0.23] [-0.45; 0.03] [-0.45; 0.03]		11.5% 17.3% 29.0% 42.1%
	Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, τ^2 Residual heterogeneity: I^2	144 = 0, <i>p</i> = = 0%, <i>p</i>	= 0.70 o = 0.70	136		Г -1	-0.5 0	0.5	ר 1		[-0.45; 0.03] [-0.45; 0.03]	100.0% 	 100.0%
0	Study		Experimental Mean SD	Total	Control Mean SD		Standardis Differe			SMD	95%-CI		Weight (random)
	g = Absorbable nasal di Ha 2017 Ha 2017 Hwang 2017 Grzeskowiak 2019 Fixed effect model Random effects model Heterogeneity: J^2 = 15%, τ^2	23 23 22 40 108 = 0.01	0.13 0.4570 0.13 0.4570 1.24 0.6600 0.21 0.4130	13 25 22 40 100	0.50 0.7970 0.20 0.5770 1.75 0.5600 0.32 0.5250			-		-0.13 -0.82 -0.23 -0.39 -0.39	[-1.30; 0.09] [-0.70; 0.44] [-1.44; -0.20] [-0.67; 0.21] [-0.66; -0.11] [-0.70; -0.09]		17.1% 24.5% 21.2% 37.2%
	Fixed effect model Random effects model Heterogeneity: $I^2 = 15\%$, τ^2 Residual heterogeneity: $I^2 =$	108 = 0.01 = 15%,	43, p = 0.32 p = 0.32	100			1 -0.5 0	0.5 1			[-0.66; -0.11] [-0.70; -0.09]	100.0% 	 100.0%
0	Study		Experimental Mean SD	Total	Control Mean SD		Standardis Differe			SMD	95%-CI		Weight (random)
	g = Absorbable nasal di Ha 2017 Ha 2017 Grzeskowiak 2019 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, $\tau^2 =$	23 23 40 58 144	0.26 0.7510 0.26 0.7510 0.25 0.4390 0.29 0.6210	13 25 40 58 136	1.00 1.2240 0.44 0.9600 0.40 0.4960 0.53 0.7540			-		-0.20 -0.32 -0.35 -0.36	[-1.47; -0.06] [-0.77; 0.36] [-0.76; 0.12] [-0.71; 0.02] [-0.60; -0.12] [-0.60; -0.12]		11.4% 17.5% 29.1% 42.0%
	Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2 = Residual heterogeneity: l^2 =	144 = 0, <i>p</i> = = 0%, <i>p</i>	= 0.66 = 0.66	136		-	1 -0.5 0	0.5 1			[-0.60; -0.12] [-0.60; -0.12]	100.0% 	 100.0%

Fig. 2. (Continued) Crusting at 2–3 weeks (E), and 2–3 months (F), nasal discharge at 2–3 weeks (G) and 2–3 months (H), edema at 2–3 weeks (I). (Continued to the next page)

difference between the two groups regarding adhesions (2–3 weeks) (P=0.5807), polypoid change (2–3 weeks) (P=0.7174), and polypoid changes (2–3 months) (P=0.4618) (Supplementary Table 4).

Sensitivity analyses

Sensitivity analyses were performed by repeating the meta-analysis several times while omitting one study on each occasion.

J _{Study}	Total	Experimental Mean SD	Total	Control Mean SD		SMD	95%-CI	Weight (fixed)	Weight (random)
g = Absorbable nasal d Ha 2017 Ha 2017 Grzeskowiak 2019 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 13%, τ ²	23 23 22 40 108	0.29 0.8040 0.29 0.8040 1.24 0.6600 0.37 0.6330	13 25 22 40 100	0.80 1.2070 0.32 0.8020 1.75 0.5600 0.68 0.7750		-0.04 -0.82 -0.43 -0.43	[-1.21; 0.18] [-0.60; 0.53] [-1.44; -0.20] [-0.88; 0.01] [-0.71; -0.15] [-0.73; -0.13]	16.2% 24.1% 20.3% 39.4% 100.0%	17.2% 24.6% 21.1% 37.1% 100.0%
Fixed effect model Random effects model Heterogeneity: $I^2 = 13\%$, τ^2	² = 0.0 ⁴	124, <i>p</i> = 0.33	100		-1 -0.5 0 0.5 1		[-0.71; -0.15] [-0.73; -0.13]	100.0% 	 100.0%
Residual heterogeneity: I ² : Study		Experimental		Contro	ol Standardised Mean	and	0.5% 01		Weight
Study	lotal	Mean SD	Total	Mean SI	D Difference	SMD	95%-CI	(fixed)	(random)
g = Drug-eluting sinus s Murr 2011 Smith 2016 Luong 2017 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, $\tau^2 =$	38 77 79 194	20.20 18.5000 24.70 27.0000 23.10 24.2000	77	30.10 22.400 41.30 29.300 35.60 31.100	0	-0.59 -0.45 -0.51	[-0.93; -0.02] [-0.91; -0.26] [-0.76; -0.13] [-0.71; -0.31] [-0.71; -0.31]	19.8% 39.5% 40.7% 100.0%	19.8% 39.5% 40.7% 100.0%
Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, $\tau_2^2 =$	194 = 0, <i>p</i> =	0.83	192				[-0.71; -0.31] [-0.71; -0.31]	100.0% 	 100.0%
Residual heterogeneity: l^2 =	= 0%, p	= 0.83			-0.5 0 0.5				
D _{Study}	Total	Experimental Mean SD		Control Mean SD		SMD	95%-CI	Weight (fixed)	Weight (random)
g = Absorbable nasal d Gyawali 2019 Fixed effect model Random effects model Heterogeneity: not applicab	58 58	0.09 0.3877	58 58	0.16 0.4885		-0.16	[-0.52; 0.21] [-0.52; 0.21] [-0.52; 0.21]	62.4% 62.4% 	62.4% 62.4%
g = Drug-eluting sinus Adriaensen 2017 Adriaensen 2017 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2	18 18 36	0.22 0.5480	18 18 36	0.56 0.7040 0.50 0.7070		-0.43 -0.47	[-1.18; 0.15] [-1.09; 0.23] [-0.94; 0.00] [-0.94; 0.00]	18.7% 18.9% 37.6% 	18.7% 18.9% 37.6%
Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ_2^2	= 0, p	= 0.57	94				[-0.56; 0.01] [-0.56; 0.01]	100.0% 	 100.0%
Residual heterogeneity: / ²		Experimental	Total	Control Mean SD		SMD	95%-CI		Weight (random)
g = Absorbable nasal d	ressir	na			1 1				
Hwang 2017 Fixed effect model Random effects model Heterogeneity: not applicab	22 22	0.76 0.6100	22 22	1.37 0.6600		-0.94	[-1.57; -0.32] [-1.57; -0.32] [-1.57; -0.32]	35.6% 35.6% 	34.9% 34.9%
g = Drug-eluting sinus : Adriaensen 2017 Adriaensen 2017 Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, τ^2 :	18 18 36	0.22 0.4277	18 18 36	0.44 0.7044 0.33 0.5940		-0.21 -0.29	[-1.03; 0.29] [-0.87; 0.45] [-0.76; 0.17] [-0.76; 0.17]	32.0% 32.4% 64.4% 	32.4% 32.7% 65.1%
Fixed effect model Random effects model Heterogeneity: $I^2 = 29\%$, τ^2 Residual heterogeneity: I^2	58 2 = 0.04	137, p = 0.25	58	-	1.5 -1 -0.5 0 0.5 1 1.	-0.52	[-0.90; -0.15] [-0.96; -0.08]	100.0% 	 100.0%

Fig. 2. (Continued) And 2–3 months (J), ethmoid inflammation at 1 month (K), polyposis at 2–3 weeks (L) and 2–3 months (M).

(Continued to the next page)

The results were consistent with those reported above.

DISCUSSION

We performed a meta-analysis of the efficacy of steroid-impregnated spacers for CRS patients undergoing ESS. Steroid-impregnated spacers reduced the LK and POSE scores and the incidence of postoperative complications, especially after 2–3 months. The steroid-impregnated spacers in this study can be divided into absorbable nasal dressings and drug-eluting sinus stents. The steroids used included triamcinolone, budesonide, betamethasone, mometasone furoate, and fluticasone propionate. In most studies, steroid-impregnated spacers were associated with better postoperative outcomes. Important postoperative parameters such as adhesion, synechia, and polypoid changes showed no significant differences between the absorbable nasal dressing and drug-eluting sinus stent groups. In this study, the number of included studies,

154 Clinical and Experimental Otorhinolaryngology Vol. 16, No. 2: 148-158, May 2023

N	Study	Experimental Events Total	Control Events Total	Odds Ratio	OR 95%-CI	Weight Weight (fixed) (random)
	g = Absorbable nasal of Ha 2017 Ha 2017 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2	3 23 3 23 3 58 104	6 13 5 25 6 58 96		0.18 [0.03; 0.89] 0.60 [0.13; 2.85] 0.47 [0.11; 1.99] 0.38 [0.16; 0.92] 0.38 [0.16; 0.92]	3.4% 3.4% 3.7% 3.7% 4.4% 4.4% 11.5% - 11.5%
	g = Drug-eluting sinus Mur 2011 Marple 2013 Adriaensen 2017 Adriaensen 2017 Luong 2017 Huang 2022 Fixed effect model Random effects model Heterogeneity. $j^2 = 0\%$, τ^2	7 38 16 85 3 18 3 18 8 77 41 181 417	6 18		0.39 [0.14; 1.11] 0.45 [0.22; 0.91] 0.40 [0.08; 1.94] 0.31 [0.07; 1.50] 0.41 [0.16; 1.02] 0.25 [0.16; 0.39] 0.32 [0.23; 0.44] 0.32 [0.23; 0.44]	8.2% 8.2% 18.2% 18.2% 3.6% 3.6% 3.7% 3.7% 11.0% 11.0% 43.8% 43.8% 88.5% - 88.5%
	Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2 Residual heterogeneity: l^2		513	0.1 0.5 1 2 10	0.33 [0.24; 0.44] 0.33 [0.24; 0.44]	100.0% 100.0%
0	Study	Experimental Events Total	Control Events Total	Odds Ratio	OR 95%-CI	Weight Weight (fixed) (random)
	g = Absorbable nasal d Ha 2017 Ha 2017 Fixed effect model Random effects model Heterogeneity: $J^2 = 2\%$, τ^2	3 23 3 23 46	5 13 4 25 38	*	0.24 [0.05; 1.25] 0.79 [0.16; 3.97] 0.44 [0.14; 1.40] 0.44 [0.14; 1.41]	12.2% 12.2% 12.7% 12.7% 24.9% 24.9%
	g = Drug-eluting sinus Adriaensen 2017 Adriaensen 2017 Huang 2022 Fixed effect model Random effects model Heteroaeneity: $j^2 = 0\%$, τ^2	3 18 3 18 8 118 154	6 18 6 18 30 118 154	*	0.40 [0.08; 1.94] 0.40 [0.08; 1.94] 0.21 [0.09; 0.49] 0.27 [0.14; 0.52] 0.27 [0.14; 0.52]	13.3% 13.3% 13.3% 13.3% 48.4% 48.4% 75.1% 75.1%
	Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2 Residual heterogeneity: l^2	= 0, p = 0.67	192	0.1 0.5 1 2 10	0.30 [0.17; 0.54] 0.30 [0.17; 0.54]	100.0% 100.0%
P	Study	Experimental Events Total		Odds Ratio	OR 95%-CI	Weight Weight (fixed) (random)
	g = Drug-eluting sinus Marple 2013 Smith 2016 Luong 2017 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2	32 96 12 79 11 75 250	45 96 27 79 17 75 250		0.57 [0.32; 1.02] 0.34 [0.16; 0.75] 0.59 [0.25; 1.35] 0.50 [0.33; 0.75] 0.50 [0.33; 0.75]	48.5% 48.5% 27.9% 27.9% 23.6% 23.6% 100.0% 100.0%
	Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, τ^2 Residual heterogeneity: I^2	250 = 0, <i>p</i> = 0.55 = 0%, <i>p</i> = 0.55	250	0.2 0.5 1 2 5	0.50 [0.33; 0.75] 0.50 [0.33; 0.75]	100.0% 100.0%

Fig. 2. (Continued) Polypoid changes at 1 month (N) and 2–3 months (O), and the need for oral steroid use (P). SD, standard deviation; SMD, standardized mean difference; CI, confidence interval.

the number of patients included, and analysis outcome items were analyzed in more than twice as many studies as in the previously reported literature [27-29]. Therefore, it was possible to obtain improved analytical power and reliability for the analyzed items. In addition, the analysis of the effects in absorbable steroid-soaked nasal spacer and steroid-eluting sinus stent groups, which are known to show greater efficacy than the control group in individual studies, demonstrated that there was no significant difference in the effect between these two treatment groups.

Evidence is accumulating that steroid-impregnated spacers

have a direct anti-inflammatory effect on inflamed sinus mucosa, and are also effective in cases of ESS-induced tissue disruption [30,31]. Furthermore, since it is difficult to precisely reach the desired site of application for topical corticosteroids, steroid-impregnated spacers could potentially be more effective than topical preparations [16]. Steroid-impregnated spacers are thought to enhance healing after surgery due to their anti-inflammatory role resulting from the steroid effects, and to prevent adhesion and synechia through the effect of the spacer [15,17]. In the sinus mucosal healing process, the first stage (1-10 days) is domi-

A	Study	Experimenta Events Tota			Odds Ratio	OR	95%-CI	Weight (fixed)	Weight (random)
	g = Absorbable nasal d Gyawali 2019 Fixed effect model Random effects model Heterogeneity: not applicab	6 58 58		58 58		0.44	[0.15; 1.27] [0.15; 1.27] [0.15; 1.27]	50.4% 50.4% 	50.4% 50.4%
	g = Drug-eluting sinus Murr 2011 Marple 2013 Huang 2022 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%, \tau^2$	2 38 2 105 1 181 324	7 1	38 - 105 - 181 324	*	0.27 1.00 0.34	[0.06; 1.57] [0.06; 1.34] [0.06; 16.11] [0.12; 0.99] [0.12; 0.99]	20.2% 22.1% 7.3% 49.6%	20.2% 22.1% 7.3% 49.6%
	Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2 Residual heterogeneity: l^2	= 0, p = 0.85		382	0.1 0.5 1 2 10		[0.18; 0.82] [0.18; 0.82]	100.0% 	 100.0%
B	Study	Experimenta Events Tota		ntrol Fotal	Odds Ratio	OR	95%-CI		Weight (random)
	g = Absorbable nasal of Ha 2017 Ha 2017 Fixed effect model Random effects model Heterogeneity: $J^2 = 0\%$, τ^2	4 23 4 23 40	3 5	13 - 25 38		0.84 0.78	[0.13; 3.77] [0.20; 3.62] [0.26; 2.34] [0.26; 2.34]	42.9% 57.1% 100.0% 	42.9% 57.1% 100.0%
	g = Drug-eluting sinus Huang 2022 Fixed effect model Random effects model Heterogeneity: not applicat	0 18 ⁻ 18 ⁻		181 181				0.0% 0.0% 	0.0% 0.0%
	Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2 Residual heterogeneity: l^2	= 0, <i>p</i> = 0.87	,	219	0.2 0.5 1 2 5		[0.26; 2.34] [0.26; 2.34]	100.0% 	 100.0%
C	Study	Experimenta Events Tota		ntrol Fotal	Odds Ratio	OR	95%-CI		Weight (random)
G	g = Absorbable nasal c Xu 2016 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, τ^2	Events Tota dressing 5 252 6 58 310 = 0, p = 0.84	2 13 3 13		Odds Ratio	0.34 0.40 0.37	95%-Cl [0.12; 0.98] [0.14; 1.14] [0.18; 0.78] [0.18; 0.78]		
G	g = Absorbable nasal o Xu 2016 Gyawali 2019 Fixed effect model Random effects model	Events Tota dressing 5 252 6 55 310 = 0, p = 0.84 stent 2 33 5 100 3 73 1 18 394	I Events 1 2 13 3 13 3 13 3 13 3 13 3 13 3 13 3 13 3 13 4 13 5 11 4 4	Fotal 233 58	Odds Ratio	0.34 0.40 0.37 0.37 0.21 0.35 0.24 0.25 0.28	[0.12; 0.98] [0.14; 1.14] [0.18; 0.78]	(fixed) 23.6% 23.7%	(random) 23.6% 23.7%
G	g = Absorbable nasal of Xu 2016 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%, \tau^2$ g = Drug-eluting sinus Murr 2011 Marple 2013 Luong 2017 Huang 2022 Fixed effect model Random effects model	Events Tota dressing 5 25; 6 58; 310; = 0, p = 0.84 stent = 0, p = 0.84 stent = 0, p = 0.95 700; = 0, p = 0.98	2 13 3 13 3 13 3 13 3 13 4 13 5 11 4	Fotal 233 58 291 38 104 75 181 -	Odds Ratio	0.34 0.40 0.37 0.37 0.21 0.35 0.24 0.25 0.28 0.28 0.28	[0.12; 0.98] [0.14; 1.14] [0.18; 0.78] [0.18; 0.78] [0.04; 1.06] [0.12; 1.03] [0.06; 0.91] [0.03; 2.22] [0.14; 0.56]	(fixed) 23.6% 23.7% 47.3% 9.8% 22.6% 14.9% 5.3% 52.7% 	(random) 23.6% 23.7% 47.3% 9.8% 22.6% 14.9% 5.3%
0	g = Absorbable nasal c Xu 2016 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2 g = Drug-eluting sinus Murr 2011 Marple 2013 Luong 2017 Huang 2022 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2	Events Tota dressing 5 25; 6 58; 310; = 0, p = 0.84 stent = 0, p = 0.84 stent = 0, p = 0.95 700; = 0, p = 0.98	I Events 1 2 13 3 13 3 13 3 8 4 13 5 11 4 3 8 1 Cor	Total 233 58 291 38 104 75 181 - 398 689 689		0.34 0.40 0.37 0.37 0.21 0.35 0.24 0.25 0.28 0.28 0.28	[0.12; 0.98] [0.14; 1.14] [0.18; 0.78] [0.18; 0.78] [0.04; 1.06] [0.12; 1.03] [0.03; 2.22] [0.14; 0.56] [0.14; 0.56] [0.19; 0.53]	(fixed) 23.6% 23.7% 47.3% 47.3% 22.6% 14.9% 5.3% 5.2% 100.0% Weight	(random) 23.6% 23.7% 47.3% 9.8% 22.6% 14.9% 5.3%
	g = Absorbable nasal c Xu 2016 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2 g = Drug-eluting sinus Murr 2011 Marple 2013 Luong 2017 Huang 2022 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2 Fixed effect model Heterogeneity: $l^2 = 0\%$, τ^2 Residual heterogeneity: l^2	Events Tota dressing 5 252 6 54 310^2 = 0, p = 0.84 stent 2 34 $5 100^3 77$ $1 18^3$ 390^2 = 0, p = 0.95 Tota = 0, p = 0.98 = 0, p = 0.98 Experimenta Events Tota dressing 2 222 2 24 $4 0^2$	I Events 7	Total 233 58 291 38 104 75 181 - 398 689 689		0.34 0.40 0.37 0.37 0.24 0.25 0.24 0.25 0.28 0.28 0.32 0.32 0.32 0.32	[0.12; 0.98] [0.14; 1.14] [0.18; 0.78] [0.18; 0.78] [0.04; 1.06] [0.12; 1.03] [0.03; 2.22] [0.14; 0.56] [0.14; 0.56] [0.19; 0.53]	(fixed) 23.6% 23.7% 47.3% 47.3% 22.6% 14.9% 5.3% 5.2% 100.0% Weight	(random) 23.6% 23.7% 47.3% 9.8% 22.6% 14.9% 5.3%
	g = Absorbable nasal c Xu 2016 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2 g = Drug-eluting sinus Murr 2011 Marple 2013 Luong 2017 Huang 2022 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, τ^2 Fixed effect model Heterogeneity: $l^2 = 0\%$, τ^2 Study g = Absorbable nasal c Ha 2017 Ha 2017 Fixed effect model Random effects model Random effects model Random effects model Random effects model	Events Tota dressing 5 265 6 50 310 = 0, p = 0.84 stent 2 36 391 = 0, p = 0.95 701 = 0, p = 0.98 = 0, p = 0.98 = 0, p = 0.98 Experimenta Events Tota dressing 2 25 2 25 2 25 2 25 2 25 3 26 4 50 2 36 3 91 = 0, p = 0.98 = 0, p	I Events T 2 13 3 13 1 11 1 11	Total 233 58 291 38 104 75 181 - 398 689 htrol Total 13 - 25		0.34 0.40 0.37 0.37 0.24 0.25 0.28 0.28 0.28 0.28 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.32	[0.12; 0.98] [0.14; 1.14] [0.18; 0.78] [0.18; 0.78] [0.18; 0.78] [0.06; 0.91] [0.06; 0.91] [0.03; 2.22] [0.14; 0.56] [0.19; 0.53] [0.19; 0.53] 95%-Cl [0.05; 2.21] [0.11; 4.61] [0.12; 1.84]	(fixed) 23.6% 23.7% 47.3% 47.3% 52.6% 14.9% 5.3% 52.7% 100.0% Weight (fixed) 12.5% 13.2%	(random) 23.6% 23.7% 47.3% 9.8% 22.6% 14.9% 5.3%

Fig. 3. Postoperative adverse outcomes: comparison between the treatment and control groups. Middle turbinate lateralization at 1 month (A), adhesions at 2 weeks (B), 1 month (C), and 2–3 months (D). (Continued to the next page)

Ø	Study	i Total I	Experimenta Mean SI	al D Total	Contr Mean S	ol Standardised Mean D Difference	SMD	95%-CI	Weight (fixed)	Weight (random)
	g = Absorbable nasal dru Ha 2017 Ha 2017 Gyawali 2019 Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 =$	23 23 58 104	0.39 0.940 0.39 0.940 0.12 0.378	0 11	0.54 1.05 0.82 1.25 0.24 0.47		-0.40 -0.28 -0.28	[-0.83; 0.53] [-1.12; 0.33] [-0.65; 0.08] [-0.57; 0.02] [-0.57; 0.02]	16.5% 64.8%	18.7% 16.5% 64.8% 100.0%
	Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 =$ Residual heterogeneity: I^2	104 0, <i>p</i> = 0%, <i>p</i>	0.88 = 0.88	82		-1 -0.5 0 0.5		[-0.57; 0.02] [-0.57; 0.02]	100.0% 	 100.0%
F	Study 1	E Total I	Experimenta Mean SE	l) Total	Contr Mean S	ol Standardised Mean D Difference	SMD	95%-CI	Weight (fixed)	Weight (random)
	g = Absorbable nasal dra Ha 2017 Ha 2017 Hwang 2017 Grzeskowiak 2019 Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 =$ Fixed effect model	23 23 22 40 108	0.22 0.7350 0.22 0.7350 0.03 0.1100 0.13 0.3430) 11) 22	0.46 0.967 0.75 1.215 0.34 0.620 0.16 0.370		-0.57 -0.68 -0.08 -0.33 -0.33	[-0.97; 0.39] [-1.30; 0.16] [-1.29; -0.07] [-0.52; 0.36] [-0.62; -0.04] [-0.62; -0.04]		18.0% 15.7% 22.6% 43.7%
	Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 =$ Residual heterogeneity: $I^2 =$		0.40 = 0.40	00		-1 -0.5 0 0.5 1		[-0.62; -0.04]	-	100.0%
G	Study		erimental ents Total		ontrol Total	Odds Ratio	OR	V 95%-CI (Veight (fixed) (Weight random)
	g = Drug-eluting sinus Marple 2013 Smith 2016 Luong 2017 Huang 2022 Fixed effect model Random effects mode Heterogeneity: $l^2 = 38\%$.	÷I	32 96 13 79 12 75 61 181 431	45 33 25 120	79 — 75 —	the second secon	0.27 [0 0.38 [0 0.26 [0 0.34 [0	.13; 0.58] .17; 0.83]	25.2% 15.5% 14.0% 45.2% 00.0% 	26.6% 19.4% 18.0% 36.1% 100.0%
	Fixed effect model Random effects mode Heterogeneity: <i>I</i> ² = 38%, Residual heterogeneity: <i>I</i> ²	el τ ² = 0.	431 0603, p = 0.		431 0	2 0.5 1 2 5		.25; 0.45] 1(.23; 0.51]	00.0% 	 100.0%
6	Study		perimental ents Total		ontrol Total	Odds Ratio	OR	V 95%-CI (Veight (fixed) (Weight random)
	g = Drug-eluting sinus Marple 2013 Smith 2016 Luong 2017 Huang 2022 Fixed effect model Random effects model Heterogeneity: / ² = 41%,	el	32 96 3 75 3 75 61 181 427	45 12 11 120	75 — 75 —		0.22 [0 0.24 [0 0.26 [0 0.33 [0	0.06; 0.81] 0.06; 0.91]	31.4% 6.2% 6.1% 56.3% 00.0% 	33.9% 11.7% 11.6% 42.8% 100.0%
	Fixed effect model Random effects mode Heterogeneity: $I^2 = 41\%$, Residual heterogeneity: I	$\tau^2 = 0.$		17	427 0	.1 0.5 1 2 10		.24; 0.45] 1(.20; 0.54]	00.0% 	 100.0%

Fig. 3. (Continued) Scarring/synechia at 2–3 weeks (E) and 2–3 months (F), non-medical or non-surgical postoperative therapeutic interventions (G), and lysis of adhesions (H). OR, odds ratio; CI, confidence interval; SD, standard deviation; SMD, standardized mean difference.

nated by blood crusting without significant changes in the underlying residual mucosa, and the second stage (up to 30 days) is dominated by edematous edema of the residual mucosa [32]. Obstructive edema, which is common in this second phase, responds well to topical steroids [32]. This might be the basis for the significant results observed in follow-up observations for more than 1 month, although several items on surgical outcomes or postoperative complication may not have shown statistically significant differences compared to the control group at 2–3 weeks postoperatively. Although absorbable nasal packing may have a shorter effect duration than drug-eluting sinus stents, the overall effect is nonetheless similar; however, additional research is needed because the number of comparative studies is small. In terms of price, steroids such as triamcinolone, dexamethasone, and betamethasone cost <\$10 USD per dose, whereas Nasopore, an absorbable nasal packing used in many studies, costs \$130 USD (for two 8-cm pieces). PROPEL sinus implants, which are used as drug-eluting sinus stents, cost \$1,390 USD (for two implants). It is necessary to consider cost-effectiveness when selecting a steroid-impregnated spacer.

This meta-analysis had several limitations. First, variables such as patients' baseline characteristics, the spacer types, and intervention period could have affected the results. Furthermore, preoperative medication, postoperative patient management, and patient compliance may have varied among the studies, and controlling for these variables is beyond the scope of a meta-analysis. More clinical trials using similar treatment regimens would be needed to overcome this issue. Second, various steroid drugs and spacers were used. To address this, we conducted a subgroup analysis of absorbable nasal dressings and drug-eluting sinus stents. Third, the final outcomes in most studies were evaluated within 3 months; however, a longer follow-up (e.g., 6 months) may be required in some patients. Therefore, well-designed largescale studies with long-term follow-up are needed. Steroid-impregnated spacers will be useful for CRS patients, as they improve the surgical outcomes of ESS patients and reduce the incidence of postoperative complications.

CONFLICT OF INTEREST

Sung Won Kim and Do Hyun Kim are editorial board members of the journal but were not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

ACKNOWLEDGMENTS

This work was supported by the National Research Foundation of Korea (NRF; 2022R1F1A1066232, 2019M3A9H2032424, 2019M3E5D5064110), and by the Ministry of Trade, Industry & Energy (MOTIE, Korea) (20012378).

ORCID

Se Hwan Hwang	https://orcid.org/0000-0002-2838-7820					
Sung Won Kim	https://orcid.org/0000-0002-8981-2536					
Mohammed Abdullah Basurrah						

 https://orcid.org/0000-0001-6214-3881

 Do Hyun Kim
 https://orcid.org/0000-0002-9248-5572

AUTHOR CONTRIBUTIONS

Conceptualization: DHK, SHH. Methodology: SWK, MAB. Formal analysis: SHH, DHK. Data curation: SWK, MAB. Visualization: SWK, MAB. Project administration: DHK, SHH. Funding acquisition: DHK, SWK. Writing–original draft: DHK, SHH. Writing–review & editing: all authors.

SUPPLEMENTARY MATERIALS

Supplementary materials can be found online at https://doi.org/ 10.21053/ceo.2022.01718.

REFERENCES

- Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020 Feb;58(Suppl 29):1-464.
- Park DY, Choi JH, Kim DK, Jung YG, Mun SJ, Min HJ, et al. Clinical practice guideline: nasal irrigation for chronic rhinosinusitis in adults. Clin Exp Otorhinolaryngol. 2022 Feb;15(1):5-23.
- Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021 Mar;11(3):213-739.
- Svider PF, Sekhsaria V, Cohen DS, Eloy JA, Setzen M, Folbe AJ. Geographic and temporal trends in frontal sinus surgery. Int Forum Allergy Rhinol. 2015 Jan;5(1):46-54.
- DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017 Mar;127(3): 550-5.
- Stein NR, Jafari A, DeConde AS. Revision rates and time to revision following endoscopic sinus surgery: a large database analysis. Laryngoscope. 2018 Jan;128(1):31-6.
- Cote DW, Wright ED. Triamcinolone-impregnated nasal dressing following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study. Laryngoscope. 2010 Jun;120(6):1269-73.
- Adriaensen GF, Lim KH, Fokkens WJ. Safety and efficacy of a bioabsorbable fluticasone propionate-eluting sinus dressing in postoperative management of endoscopic sinus surgery: a randomized clinical trial. Int Forum Allergy Rhinol. 2017 Aug;7(8):813-20.
- Grzeskowiak B, Wierzchowska M, Walorek R, Seredyka-Burduk M, Wawrzyniak K, Burduk PK. Steroid vs. antibiotic impregnated absorbable nasal packing for wound healing after endoscopic sinus surgery: a randomized, double blind, placebo-controlled study. Braz J Otorhinolaryngol. 2019 Jul-Aug;85(4):473-80.
- Gyawali BR, Pradhan B, Thapa N. Comparison of outcomes of triamcinolone versus normal saline soaked polyvinyl alcohol pack following bilateral endoscopic sinus surgery. Rhinology. 2019 Aug;57(4): 287-92.
- Ha T, Valentine R, Moratti S, Hanton L, Robinson S, Wormald PJ. The efficacy of a novel budesonide chitosan gel on wound healing following endoscopic sinus surgery. Int Forum Allergy Rhinol. 2018 Mar; 8(3):435-43.
- 12. Huang Z, Zhou B, Wang D, Zang H, Zhang H, Wang H, et al. Comparison of bioabsorbable steroid-eluting sinus stents versus nasopore after endoscopic sinus surgery: a multicenter, randomized, controlled, single-blinded clinical trial. Ear Nose Throat J. 2022 May;101(4): 260-7.
- Hwang CS, Al Sharhan SS, Kim BR, Kim SI, Kim JW, Cho HJ, et al. Randomized controlled trial of steroid-soaked absorbable calcium alginate nasal packing following endoscopic sinus surgery. Laryngoscope. 2018 Feb;128(2):311-6.
- 14. Luong A, Ow RA, Singh A, Weiss RL, Han JK, Gerencer R, et al. Safety and effectiveness of a bioabsorbable steroid-releasing implant for the paranasal sinus ostia: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2018 Jan;144(1):28-35.
- 15. Marple BF, Smith TL, Han JK, Gould AR, Jampel HD, Stambaugh JW,

et al. Advance II: a prospective, randomized study assessing safety and efficacy of bioabsorbable steroid-releasing sinus implants. Otolaryngol Head Neck Surg. 2012 Jun;146(6):1004-11.

- More Y, Willen S, Catalano P. Management of early nasal polyposis using a steroid-impregnated nasal dressing. Int Forum Allergy Rhinol. 2011 Sep-Oct;1(5):401-4.
- Murr AH, Smith TL, Hwang PH, Bhattacharyya N, Lanier BJ, Stambaugh JW, et al. Safety and efficacy of a novel bioabsorbable, steroideluting sinus stent. Int Forum Allergy Rhinol. 2011 Jan-Feb;1(1): 23-32.
- Rudmik L, Mace J, Mechor B. Effect of a dexamethasone Sinu-Foam-TM middle meatal spacer on endoscopic sinus surgery outcomes: a randomized, double-blind, placebo-controlled trial. Int Forum Allergy Rhinol. 2012 May-Jun;2(3):248-51.
- Sabarinath V, Harish MR, Divakaran S. Triamcinolone impregnated nasal pack in endoscopic sinus surgery: our experience. Indian J Otolaryngol Head Neck Surg. 2017 Mar;69(1):88-92.
- Samarei R, Rasouli J, Mehdikhani F. Efficacy of triamcinolone acetonide-impregnated Gelfoam nasal pack in management of chronic sinusitis with nasal polyps following endoscopic sinus surgery: a perfectly matched, placebo-controlled trial study. Eur Arch Otorhinolaryngol. 2022 Jun;279(6):2915-24.
- Smith TL, Singh A, Luong A, Ow RA, Shotts SD, Sautter NB, et al. Randomized controlled trial of a bioabsorbable steroid-releasing implant in the frontal sinus opening. Laryngoscope. 2016 Dec;126(12): 2659-64.
- Xu J, Park SJ, Park HS, Han R, Rha KS, Kim YM. Effects of triamcinolone-impregnated nasal dressing on subjective and objective outcomes following endoscopic sinus surgery. Eur Arch Otorhinolaryngol. 2016 Dec;273(12):4351-7.
- 23. Zhao KQ, Yu YQ, Yu HM. Effects of mometasone furoate-impregnated biodegradable nasal dressing on endoscopic appearance in healing process following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study. Int Forum Allergy Rhinol. 2018

Nov;8(11):1233-41.

- 24. Kim DH, Kim SW, Basurrah MA, Hwang SH. Clinical and laboratory features of various criteria of eosinophilic chronic rhinosinusitis: a systematic review and meta-analysis. Clin Exp Otorhinolaryngol. 2022 Aug;15(3):230-46.
- Hwang SH, Kim JS, Choi BY, Kim JK, Kim BG. Practical review of olfactory training and COVID-19. J Rhinol. 2022;29(3):127-33.
- 26. Wright ED, Agrawal S. Impact of perioperative systemic steroids on surgical outcomes in patients with chronic rhinosinusitis with polyposis: evaluation with the novel Perioperative Sinus Endoscopy (POSE) scoring system. Laryngoscope. 2007 Nov;117(11 Pt 2 Suppl 115): 1-28.
- Li W, Lu H, Wang H, Sun X, Wang D. Efficacy and safety of steroidimpregnated implants following sinus surgery: a meta-analysis. Laryngoscope. 2020 Dec;130(12):2754-9.
- Stefan MM, Rabie NA, Sobhy TS, Maarouf AM. Effect of steroid-releasing sinus implants after endoscopic sinus surgery (ESS) on postoperative outcomes: a meta-analytical study. Egypt J Otolaryngol. 2019 Jul;35:250-5.
- Zhao X, Grewal A, Briel M, Lee JM. A systematic review of nonabsorbable, absorbable, and steroid-impregnated spacers following endoscopic sinus surgery. Int Forum Allergy Rhinol. 2013 Nov;3(11): 896-904.
- 30. Goshtasbi K, Abouzari M, Abiri A, Yasaka T, Sahyouni R, Bitner B, et al. Efficacy of steroid-eluting stents in management of chronic rhinosinusitis after endoscopic sinus surgery: updated meta-analysis. Int Forum Allergy Rhinol. 2019 Dec;9(12):1443-50.
- Zhang M, Ryan PJ, Shashinder S. Efficacy of absorbable steroid-impregnated nasal packing in functional endoscopic sinus surgery for chronic rhinosinusitis: a systematic review. Laryngoscope. 2021 Aug; 131(8):1704-14.
- Hosemann W, Wigand ME, Gode U, Langer F, Dunker I. Normal wound healing of the paranasal sinuses: clinical and experimental investigations. Eur Arch Otorhinolaryngol. 1991;248(7):390-4.